Biocytogen Pharmaceuticals and Pheon Therapeutics Announced a License Agreement
Thursday, July 06, 2023
Biocytogen Pharmaceuticals announced a licence agreement with Pheon Therapeutics regarding the development and commercialisation of an antibody.
Under the terms of the agreement, Pheon will develop and commercialise an antibody developed on Biocytogen's proprietary RenMiceTM platforms.
As part of the agreement, Biocytogen will receive an upfront payment and will also be eligible for milestone payments during the development and commercialisation process. Additionally, Biocytogen will receive single-digit royalties on net sales.
The licence agreement between Biocytogen and Pheon represents a significant expansion of Pheon's pipeline and will contribute to their ability to develop the next generation of ADCs (antibody-drug conjugates).
The combination of strengths between fully human antibody discovery and ADC (Antibody-Drug Conjugate) technologies has the potential to greatly accelerate the development of new medicines that can benefit patients.
RenMiceTM platforms offer a unique approach by completely replacing the variable genes of human antibodies in situ. RenMiceTM platforms has the ability to generate antibodies with low immunogenicity. Immunogenicity refers to the potential of an antibody to elicit an immune response in the body, which can reduce its effectiveness and lead to unwanted side effects.
